Baolingbao Biology (002286.SZ) announced its performance forecast for the first half of 2024, with a net profit attributable to shareholders of the listed company of 58-75 million yuan, an increase of 77.05%-128.94% compared to the same period last year; the net profit after deducting non-recurring gains and losses was 57-70 million yuan, an increase of 212.55%-283.83% compared to the same period last year; and the basic earnings per share were 0.1595 yuan/share to 0.2038 yuan/share.
Since 2023, the company has optimized the production process of probiotics, dietary fiber, and sugar substitute products, strengthened cost control, and reduced production costs compared with the same period last year; in the first half of 2024, the main raw material, corn and corn starch, as well as the purchase price of energy such as steam, have decreased to a certain extent compared with the same period in 2023; the company has adjusted its marketing strategy, strengthened incentives for sales differentiation and high-margin products, improved the product structure, and significantly improved the gross margin.